Ab0660 Predictive Factors for Good Response to Rheumatoid Arthritis With Biological Targeted Therapies

Background: Determination of predictive factors for good response or tolerance to basic biological treatments helps guide the prescription and helps to make a choice according to patient profile. Certain clinical and paraclinical elements have been identified during clinical studies, however data from the literature on this subject are sometimes discordant. Objectives: The objective of this work is to analyze the response clinic of patients with Rheumatoid Arthritis (RA) treated with biomedicines and determine the factors associated with the correct response therapeutic. Methods: This is a prospective observational study carried out in a health service rheumatology from January 2010 to December 2021. Including patients with Rheumatoid Arthritis diagnosed according to ACR/EULAR criteria in failure or intolerance to csDMARD and treated with biomedications. We analyzed the therapeutic response evaluated at 3, 6 and 12 months to biological treatments on the based on the DAS28 score and EULAR response criteria judged to be good or moderate. Binary logistic regression was done to identify the predictive factors of good clinical response to biotherapies. Results: The study involved 121 patients (104 women, 17 men), the average age was 45.83±14.55 years and the average duration of disease progression was 11.02±9.4 years. The average Number of Painful Joints (NPJ) and synovitis was of 11.21±5.9 and 6.46±2.94 respectively. The average duration of stiffness morning was 91.98±39.76 minutes. 64.5% of patients had at least one comorbidity associated with RA. A biological inflammatory syndrome was noted in all patients (mean ESR=55.01±23.44mm/1h, CRP average=28.18±22.29mg/l). The FR was positive in 66.9% of patients and ACPA at 75.2%. Joint deformities were present in 86.8%. All patients had active RA before biotherapy with a DAS28 score average initial of 5.42±0.75.54.5% of patients were treated with Rituximab, 16.5% by Tocilizumab, 15.7% by Adalimumab and 13.2% by Etanercept. There EULAR remission achieved in 116 patients was 79.3% at 3 months, 82.2% at 6 months in a total of 112 patients and 85.1% at 12 months in 101 cases studied. The percentage of EULAR responses judged good or moderate was 75.9%, 83.9% and 86.1% at 3, 6 and 12 months respectively. The multivariate analysis found a significant association between remission and NPJ (OR:1.106 (1.018-1.201), P Conclusion: Factors that can be predictive of response to targeted biological therapies are increasingly studied with a view to better targeting patients potentially good responders. A significant link between NPJ, the number of comorbidities associated with RA, Duration of Morning Stiffness, ESR and good response therapy with biomedicines was identified in our study. REFERENCES: NIL. Acknowledgements: NIL. Disclosure of Interests: None declared.